ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parkes, J.
Right arrow Articles by Templeton, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parkes, J.
Right arrow Articles by Templeton, D.
Annals of Clinical and Laboratory Science, Vol 24, Issue 6, 509-520
Copyright © 1994 by Association of Clinical Scientists


Articles

Iron transport and subcellular distribution in Hep G2 hepatocarcinoma cells

JG Parkes and DM Templeton

Thalassemic patients with iron overload are presently treated with deferoxamine or the experimental chelator deferiprone. To understand how these agents remove iron from the liver, cultured human hepatoma cells loaded with iron were previously used as a model for hepatic iron overload. The present study was undertaken to characterize further the pathways of iron transport and distribution in these cells. The activation energy for Fe2+ transport is 19 kJ/mol greater than for Fe3+, and the rate of Fe2+ transport--but not that of Fe3(+)--decreases with temperature above 25 degrees C, suggesting distinct uptake processes for different redox states of iron. Iron loading, which promotes a greater rate of Fe3+ transport, also caused a proportionally greater deposition of iron in the microsomal and cytosolic compartments and specifically lowered the activities of succinate-cytochrome c reductase and 5'-nucleotidase, representative markers of the mitochondria and plasma membrane, respectively. Both deferiprone and deferoxamine decreased total cellular iron and iron in each fraction except cytosol, indicating mobilization of iron for clearance from the cell via the cytosol. This model may be useful in characterizing the determinants of effective chelation in patients.


This article has been cited by other articles:


Home page
Annals of Clinical & Laboratory ScienceHome page
J. G. Parkes and D. M. Templeton
Effects of Retinol and Hepatocyte-Conditioned Medium on Cultured Rat Hepatic Stellate Cells
Ann. Clin. Lab. Sci., July 1, 2003; 33(3): 295 - 305.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Cragg, R. P. Hebbel, W. Miller, A. Solovey, S. Selby, and H. Enright
The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells
Blood, July 15, 1998; 92(2): 632 - 638.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Association of Clinical Scientists.